Literature DB >> 31531686

[Indications for varicella zoster and herpes zoster vaccination in multiple sclerosis: current situation].

Alexander Winkelmann1, Micha Löbermann2, Uwe K Zettl3,4.   

Abstract

In patients with multiple sclerosis (MS) primary varicella zoster virus (VZV) infections (chickenpox) or reactivation (shingles, herpes zoster) pose a particular challenge for neurologists and physicians in everyday clinical practice. On the one hand the various immunotherapeutic agents for treatment of MS have differently expressed risks for VZV-associated infections and on the other hand the currently available vaccination strategies (dead vs. live vaccines, single vs. combination vaccines) require an individualized approach. Moreover, in addition to the optimal timing of vaccination during the course of MS, the appropriate vaccine and, where indicated, the use of antiviral drugs should be determined.

Entities:  

Keywords:  Chickenpox; Disease-modifying drugs; Multiple sclerosis; Shingles; Vaccination

Year:  2019        PMID: 31531686     DOI: 10.1007/s00115-019-00806-x

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  25 in total

1.  Background paper to the decision to recommend the vaccination with the inactivated herpes zoster subunit vaccine : Statement of the German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute.

Authors:  A Siedler; J Koch; E Garbe; H Hengel; R von Kries; T Ledig; T Mertens; F Zepp; K Überla
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2019-03       Impact factor: 1.513

2. 

Authors:  Norbert Wagner; Frauke Assmus; Gabriele Arendt; Erika Baum; Ulrich Baumann; Christian Bogdan; Gerd Burchard; Dirk Föll; Edeltraut Garbe; Jane Hecht; Ulf Müller-Ladner; Tim Niehues; Klaus Überla; Sabine Vygen-Bonnet; Thomas Weinke; Miriam Wiese-Posselt; Michael Wojcinski; Fred Zepp
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2019-04       Impact factor: 1.513

3.  Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study.

Authors:  Massimo Filippi; Paolo Preziosa; Alessandro Meani; Olga Ciccarelli; Sarlota Mesaros; Alex Rovira; Jette Frederiksen; Christian Enzinger; Frederik Barkhof; Claudio Gasperini; Wallace Brownlee; Jelena Drulovic; Xavier Montalban; Stig P Cramer; Alexander Pichler; Marloes Hagens; Serena Ruggieri; Vittorio Martinelli; Katherine Miszkiel; Mar Tintorè; Giancarlo Comi; Iris Dekker; Bernard Uitdehaag; Irena Dujmovic-Basuroski; Maria A Rocca
Journal:  Lancet Neurol       Date:  2017-12-21       Impact factor: 44.182

4.  Complications of herpes zoster in immunocompetent older adults: Incidence in vaccine and placebo groups in two large phase 3 trials.

Authors:  Martina Kovac; Himal Lal; Anthony L Cunningham; Myron J Levin; Robert W Johnson; Laura Campora; Antonio Volpi; Thomas C Heineman
Journal:  Vaccine       Date:  2018-02-17       Impact factor: 3.641

Review 5.  Multiple sclerosis.

Authors:  Alan J Thompson; Sergio E Baranzini; Jeroen Geurts; Bernhard Hemmer; Olga Ciccarelli
Journal:  Lancet       Date:  2018-03-23       Impact factor: 79.321

Review 6.  Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.

Authors:  Paulus S Rommer; Uwe K Zettl
Journal:  Expert Opin Pharmacother       Date:  2018-03-12       Impact factor: 3.889

Review 7.  Varicella-zoster virus infection: natural history, clinical manifestations, immunity and current and future vaccination strategies.

Authors:  Giulia Freer; Mauro Pistello
Journal:  New Microbiol       Date:  2018-03-02       Impact factor: 2.479

8.  [Fingolimod treatment for multiple sclerosis patients. Infectiological aspects and recommendations for vaccinations].

Authors:  A Winkelmann; M Löbermann; E C Reisinger; U K Zettl
Journal:  Nervenarzt       Date:  2012-02       Impact factor: 1.214

9.  Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.

Authors:  Anthony L Cunningham; Himal Lal; Martina Kovac; Roman Chlibek; Shinn-Jang Hwang; Javier Díez-Domingo; Olivier Godeaux; Myron J Levin; Janet E McElhaney; Joan Puig-Barberà; Carline Vanden Abeele; Timo Vesikari; Daisuke Watanabe; Toufik Zahaf; Anitta Ahonen; Eugene Athan; Jose F Barba-Gomez; Laura Campora; Ferdinandus de Looze; H Jackson Downey; Wayne Ghesquiere; Iris Gorfinkel; Tiina Korhonen; Edward Leung; Shelly A McNeil; Lidia Oostvogels; Lars Rombo; Jan Smetana; Lily Weckx; Wilfred Yeo; Thomas C Heineman
Journal:  N Engl J Med       Date:  2016-09-15       Impact factor: 91.245

10.  Varicella zoster virus infections in neurological patients: a clinical study.

Authors:  Thomas Skripuletz; Kaweh Pars; Alina Schulte; Philipp Schwenkenbecher; Özlem Yildiz; Tina Ganzenmueller; Maike Kuhn; Annette Spreer; Ulrich Wurster; Refik Pul; Martin Stangel; Kurt-Wolfram Sühs; Corinna Trebst
Journal:  BMC Infect Dis       Date:  2018-05-25       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.